These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 12036210)

  • 1. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis.
    Sarzi-Puttini P; Cazzola M; Panni B; Turiel M; Fiorini T; Belai-Beyene N; Chèrié-Lignièré EL
    Rheumatol Int; 2002 Apr; 21(6):234-8. PubMed ID: 12036210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment of systemic lupus erythematosus with cyclosporin A.
    Caccavo D; Laganà B; Mitterhofer AP; Ferri GM; Afeltra A; Amoroso A; Bonomo L
    Arthritis Rheum; 1997 Jan; 40(1):27-35. PubMed ID: 9008597
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Results of leflunomide treatment of psoriatic arthritis].
    Pchelintseva AO; Korotaeva TV; Godzenko AA; Korsakova IuL; Stanislav ML; Denisov LN
    Ter Arkh; 2007; 79(8):22-8. PubMed ID: 17926466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary focus on cyclosporin A.
    Salvarani C; Boiardi L; Macchioni P; Pipitone N; Catanoso M; Pigatto P
    J Rheumatol Suppl; 2009 Aug; 83():52-5. PubMed ID: 19661542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy with cyclosporine in psoriatic arthritis.
    Olivieri I; Salvarani C; Cantini F; Macchioni L; Padula A; Niccoli L; Boiardi L; Portioli I
    Semin Arthritis Rheum; 1997 Aug; 27(1):36-43. PubMed ID: 9287388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study.
    Voulgari PV; Venetsanopoulou AI; Exarchou SA; Alamanos Y; Tsifetaki N; Drosos AA
    Semin Arthritis Rheum; 2008 Apr; 37(5):293-8. PubMed ID: 17888499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.
    Spadaro A; Riccieri V; Sili-Scavalli A; Sensi F; Taccari E; Zoppini A
    Clin Exp Rheumatol; 1995; 13(5):589-93. PubMed ID: 8575136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of cyclosporine A as monotherapy in patients with psoriatic arthritis: a subgroup analysis of the SYNERGY Study.
    Colombo D; Chimenti S; Grossi PA; Marchesoni A; Foti R; Calzavara-Pinton P; Zagni E; Ori A; Bellia G;
    G Ital Dermatol Venereol; 2017 Jun; 152(3):297-301. PubMed ID: 26837484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
    Fraser AD; van Kuijk AW; Westhovens R; Karim Z; Wakefield R; Gerards AH; Landewé R; Steinfeld SD; Emery P; Dijkmans BA; Veale DJ
    Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.
    Salvarani C; Macchioni P; Olivieri I; Marchesoni A; Cutolo M; Ferraccioli G; Cantini F; Salaffi F; Padula A; Lovino C; Dovigo L; Bordin G; Davoli C; Pasero G; Alberighi OD
    J Rheumatol; 2001 Oct; 28(10):2274-82. PubMed ID: 11669169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.
    Gladman DD; Mease PJ; Ritchlin CT; Choy EH; Sharp JT; Ory PA; Perdok RJ; Sasso EH
    Arthritis Rheum; 2007 Feb; 56(2):476-88. PubMed ID: 17265483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A.
    Gül U; Gönül M; Kiliç A; Erdem R; Cakmak SK; Gündüz H
    Clin Ther; 2006 Feb; 28(2):251-4. PubMed ID: 16678646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
    Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
    Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy.
    Salvarani C; Macchioni P; Boiardi L; Rossi F; Casadei Maldini M; Mancini R; Beltrandi E; Lodi L; Bisighini G; Portioli I
    J Rheumatol; 1992 Jan; 19(1):74-9. PubMed ID: 1556703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial.
    Karanikolas GN; Koukli EM; Katsalira A; Arida A; Petrou D; Komninou E; Fragiadaki K; Zacharioudaki A; Lasithiotakis I; Giavri E; Vaiopoulos G; Sfikakis PP
    J Rheumatol; 2011 Nov; 38(11):2466-74. PubMed ID: 21885499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin-A.
    Macchioni P; Boiardi L; Cremonesi T; Battistel B; Casadei-Maldini M; Beltrandi E; Mancini R; Salvarani C
    Rheumatol Int; 1998; 18(1):27-33. PubMed ID: 9672996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study).
    Migliore A; Bizzi E; Massafra U; Vacca F; Martin Martin LS; Ferlito C; Podestà E; Granata M; Laganà B
    Int J Immunopathol Pharmacol; 2010; 23(3):783-90. PubMed ID: 20943048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
    Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
    Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study.
    Mazzotta A; Esposito M; Schipani C; Chimenti S
    J Dermatolog Treat; 2009; 20(6):354-8. PubMed ID: 19954392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.